YMAB Y-mAbs Therapeutics Inc.

35.8
+0.84  (+2%)
Previous Close 34.96
Open 35.24
Price To Book 16.57
Market Cap 1,422,277,293
Shares 39,728,416
Volume 115,166
Short Ratio
Av. Daily Volume 265,063
Stock charts supplied by TradingView

NewsSee all news

  1. Y-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  2. Y-mAbs Announces Positive Naxitamab Frontline Data

    NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  3. Y-mAbs and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for Omburtamab

    NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  4. Y-mAbs to Host R&D Event and Live Webcast on Wednesday, December 11

    NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  5. Y-mAbs Initiates Rolling Submission of Biologics License Application to U.S. FDA for Naxitamab for Treatment of Neuroblastoma

    NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Rolling BLA filing commenced November 29, 2019 and to be completed by 1Q 2020.
Naxitamab
Relapsed/Refractory High-Risk Neuroblastoma
BLA filing due 1Q 2020.
Omburtamab
CNS/Leptomeningeal Metastases from Neuroblastoma

Latest News

  1. Y-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  2. Y-mAbs Announces Positive Naxitamab Frontline Data

    NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  3. Y-mAbs and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for Omburtamab

    NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  4. Y-mAbs to Host R&D Event and Live Webcast on Wednesday, December 11

    NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  5. Y-mAbs Initiates Rolling Submission of Biologics License Application to U.S. FDA for Naxitamab for Treatment of Neuroblastoma

    NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  6. Y-mAbs Announces Update on Omburtamab in DSRCT

    NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  7. Y-mAbs Announces Third Quarter 2019 Financial Results and Recent Corporate Developments

    NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel,

  8. Y-mAbs to Announce Third Quarter 2019 Financial and Operating Results on November 13

    NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its third quarter 2019 financial and operating results on Wednesday,

  9. Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  10. Y-mAbs Announces Naxitamab Update

    NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (NASDAQ:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel,

  11. Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees

    Believes its Five Completely Independent Nominees Would Bring Much-Needed Skill Sets and Drastically Improve the Board's Strategic Oversight and Corporate Governance Failings Expresses Disappointment with Current